Distinction between benign and malignant type of parkinson's disease
- 31 December 1979
- journal article
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 81 (3), 158-164
- https://doi.org/10.1016/0303-8467(79)90003-9
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASEThe Lancet, 1977
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenilJournal of Neural Transmission, 1975
- Responsibility of extrastriatal areas for the appearance of psychotic symptoms (Clinical and biochemical human post-mortem findings)Journal of Neural Transmission, 1975
- Nucleus ruber and L-Dopa psychosis: Biochemical post-mortem findingsJournal of Neural Transmission, 1974
- Longevity in Parkinson's disease treated with L-DOPAClinical Neurology and Neurosurgery, 1974
- Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlationsJournal of the Neurological Sciences, 1973
- L-dopa level in plasma, primary condition for the kinetic effectJournal of Neural Transmission, 1973
- Levodopa in the Treatment of ParkinsonismPublished by American Medical Association (AMA) ,1971
- Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylaseJournal of Pharmacy and Pharmacology, 1968
- Weitere experimentelle Untersuchungen über den Catecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson- und Chorea-Syndrom)Archiv Fur Psychiatrie Und Nervenkrankheiten, 1967